Drug: Daratumumab (Darzalex, Janssen)
Status: Granted breakthrough therapy status for use with dexamethasone and either lenalidomide (Revlimid, Celgene) or bortezomib (Velcade, Millennium/Takeda) for patients with previously treated multiple myeloma
Significant Trial Data:
Phase III CASTOR trial:
- Daratumumab plus bortezomib-dexamethasone versus bortezomib and dexamethasone
- 498 patients who had received at least 1 prior treatment for MM
- After 7.4 months median follow-up, daratumumab recipients